BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahler M. Lack of standardisation of ANA and implications for drug development and precision medicine. Ann Rheum Dis 2019;78:e33. [PMID: 29574414 DOI: 10.1136/annrheumdis-2018-213374] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Cinquanta L, Bizzaro N, Pesce G. Standardization and Quality Assessment Under the Perspective of Automated Computer-Assisted HEp-2 Immunofluorescence Assay Systems. Front Immunol 2021;12:638863. [PMID: 33717188 DOI: 10.3389/fimmu.2021.638863] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
2 Van Hoovels L, Bossuyt X, Manfredi M, Grossi V, Benucci M, Van Den Bremt S, De Baere H, Franceschi D, Tosi E, Meoni M, Bizzaro N, Infantino M. Integrating quality assurance in autoimmunity: the changing face of the automated ANA IIF test. Clin Chem Lab Med 2021;59:1247-55. [PMID: 33594844 DOI: 10.1515/cclm-2020-1669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Van Hoovels L, Broeders S, Chan EKL, Andrade L, de Melo Cruvinel W, Damoiseaux J, Viander M, Herold M, Coucke W, Heijnen I, Bogdanos D, Calvo-Alén J, Eriksson C, Kozmar A, Kuhi L, Bonroy C, Lauwerys B, Schouwers S, Lutteri L, Vercammen M, Mayer M, Patel D, Egner W, Puolakka K, Tesija-Kuna A, Shoenfeld Y, de Sousa MJR, Hoyos ML, Radice A, Bossuyt X. Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey. Auto Immun Highlights 2020;11:17. [PMID: 33228811 DOI: 10.1186/s13317-020-00139-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Infantino M, Carbone T, Manfredi M, Grossi V, Antico A, Panozzo MP, Brusca I, Alessio MG, Previtali G, Platzgummer S, Cinquanta L, Paura G, Deleonardi G, Trevisan MT, Radice A, Castiglione C, Imbastaro T, Fabris M, Pesce G, Porcelli B, Terzuoli L, Sorrentino MC, Tampoia M, Abbracciavento L, Villalta D, Conte M, Barberio G, Gallo N, Benucci M, Bizzaro N; Study Group on Autoimmune Diseases of the Italian Society of Clinical Pathology and Laboratory Medicine. A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: A pilot study. Autoimmun Rev 2020;19:102588. [PMID: 32540447 DOI: 10.1016/j.autrev.2020.102588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Pisetsky DS, Spencer DM, Rovin B, Lipsky PE. Role of ANA testing in the classification of patients with systemic lupus erythematosus. Ann Rheum Dis 2021;80:e124-e124. [DOI: 10.1136/annrheumdis-2019-216259] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fritzler MJ, Mahler M. Redefining systemic lupus erythematosus - SMAARTT proteomics. Nat Rev Rheumatol 2018;14:451-2. [PMID: 29907860 DOI: 10.1038/s41584-018-0035-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
7 Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al. Ann Rheum Dis 2020;79:e66. [PMID: 31076389 DOI: 10.1136/annrheumdis-2019-215479] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Pollard KM, Cauvi DM, Toomey CB, Hultman P, Kono DH. Mercury-induced inflammation and autoimmunity. Biochim Biophys Acta Gen Subj 2019;1863:129299. [PMID: 30742953 DOI: 10.1016/j.bbagen.2019.02.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
9 Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro. Ann Rheum Dis 2020;79:e33. [PMID: 30659048 DOI: 10.1136/annrheumdis-2018-214829] [Reference Citation Analysis]
10 Bogaert L, Van den Bremt S, Schouwers S, Bossuyt X, Van Hoovels L. Harmonizing by reducing inter-run variability: performance evaluation of a quality assurance program for antinuclear antibody detection by indirect immunofluorescence. Clinical Chemistry and Laboratory Medicine (CCLM) 2019;57:990-8. [DOI: 10.1515/cclm-2018-0933] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Bizzaro N. Can solid-phase assays replace immunofluorescence for ANA screening? Ann Rheum Dis 2020;79:e32. [PMID: 30530824 DOI: 10.1136/annrheumdis-2018-214805] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
12 Pisetsky DS, Spencer DM, Lipsky PE, Rovin B. Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco et al. Ann Rheum Dis 2020;79:e7. [PMID: 30504443 DOI: 10.1136/annrheumdis-2018-214766] [Reference Citation Analysis]
13 Van Hoovels L, Bossuyt X. Harmonisation of laboratory tests for rheumatic diseases: still a long way to go. Ann Rheum Dis 2020;79:e5. [PMID: 30514700 DOI: 10.1136/annrheumdis-2018-214696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
14 Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Response to: 'ANA testing in "real life"' by Infantino et al. Ann Rheum Dis 2020;79:e4. [PMID: 30448767 DOI: 10.1136/annrheumdis-2018-214650] [Reference Citation Analysis]
15 Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al. Ann Rheum Dis 2019;78:e77. [PMID: 29936440 DOI: 10.1136/annrheumdis-2018-213841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Willems P, De Langhe E, Westhovens R, Vanderschueren S, Blockmans D, Bossuyt X. Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities. Ann Rheum Dis 2019;78:e76-e76. [DOI: 10.1136/annrheumdis-2018-213821] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
17 Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al. Ann Rheum Dis 2019;78:e49. [PMID: 29730638 DOI: 10.1136/annrheumdis-2018-213558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al. Ann Rheum Dis 2019;78:e51. [PMID: 29730639 DOI: 10.1136/annrheumdis-2018-213582] [Reference Citation Analysis]
19 Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al. Ann Rheum Dis 2019;78:e47. [PMID: 29705742 DOI: 10.1136/annrheumdis-2018-213537] [Reference Citation Analysis]
20 Pregnolato F, Borghi MO, Meroni PL. Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. Ann Rheum Dis 2019;78:e50-e50. [DOI: 10.1136/annrheumdis-2018-213516] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
21 Van Hoovels L, Schouwers S, Van den Bremt S, Bossuyt X. Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis. Ann Rheum Dis 2019;78:e48. [PMID: 29678938 DOI: 10.1136/annrheumdis-2018-213543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
22 Meroni PL, Chan EK, Damoiseaux J, Andrade LEC, Bossuyt X, Conrad K, Mariette X, Sheldon J, Rönnelid J, Fritzler MJ. Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions? Ann Rheum Dis 2019;78:e46-e46. [DOI: 10.1136/annrheumdis-2018-213440] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
23 Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler. Ann Rheum Dis 2019;78:e34. [PMID: 29592916 DOI: 10.1136/annrheumdis-2018-213399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]